Vascular smooth muscle dysfunction induced by monomethylarsonous acid (MMA(III)): A contributing factor to arsenic-associated cardiovascular diseases

While arsenic in drinking water is known to cause various cardiovascular diseases in human, exact mechanism still remains elusive. Recently, trivalent-methylated arsenicals, the metabolites of inorganic arsenic, were shown to have higher cytotoxic potential than inorganic arsenic. To study the role of these metabolites in arsenic-induced cardiovascular diseases, we investigated the effect of monomethylarsonous acid (MMA(III)), a major trivalent-methylated arsenical, on vasomotor tone of blood vessels. In isolated rat thoracic aorta and small mesenteric arteries, MMA(III) irreversibly suppressed normal vasoconstriction induced by three distinct agonists of phenylephrine (PE), serotonin and endothelin-1. Inhibition of vasoconstriction was retained in aortic rings without endothelium, suggesting that MMA(III) directly impaired the contractile function of vascular smooth muscle. The effect of MMA(III) was mediated by inhibition of PE-induced Ca2+ increase as found in confocal microscopy and fluorimeter in-lined organ chamber technique. The attenuation of Ca2+ increase was from concomitant inhibition of release from intracellular store and extracellular Ca2+ influx via L-type Ca2+ channel, which was blocked by MMA(III) as shown in voltage-clamp assay in Xenopus oocytes. MMA(III) did not affect downstream process of Ca2+, as shown in permeabilized arterial strips. In in vivo rat model, MMA(III) attenuated PE-induced blood pressure increase indeed, supporting the clinical relevance of these in vitro findings. In conclusion, MMA(III)-incluced smooth muscle dysfunction through disturbance of Ca2+ regulation, which results in impaired vasoconstriction and aberrant blood pressure change. This study will provide a new insight into the role of trivalent-methylated arsenicals in arsenic-associated cardiovascular diseases. (C) 2008 Elsevier Inc. All rights reserved.This work was supported by the NITR project from the Korea Food Drug Administration (KFDA) and the SRC/ERC program of MCIST/KCISEF (R11-2007-107-01002-0)